418.58
United Therapeutics Corp (UTHR) 最新ニュース
How United Therapeutics Corporation (UTH) stock benefits from digital adoptionJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Will United Therapeutics Corporation benefit from macro trends2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
What data driven models say about United Therapeutics Corporation’s future2025 Sector Review & Fast Moving Stock Watchlists - newser.com
Risk adjusted return profile for United Therapeutics Corporation analyzedJuly 2025 Volume & Fast Gain Swing Trade Alerts - newser.com
What makes United Therapeutics Corporation stock attractive to growth fundsTrade Risk Assessment & Precise Trade Entry Recommendations - newser.com
United Therapeutics Executives Sell Shares - TradingView
United Therapeutics EVP & General Counsel Sells 11,000 Shares - TradingView
Why United Therapeutics Corporation (UTH) stock gets analyst attention2025 Buyback Activity & Reliable Momentum Entry Alerts - newser.com
What margin trends mean for United Therapeutics Corporation stockWeekly Market Outlook & Entry Point Confirmation Signals - newser.com
United Therapeutics Corporation (UTHR) Stock forecasts - Yahoo
Will United Therapeutics Corporation (UTH) stock attract long term capital inflowsJuly 2025 Setups & Weekly High Potential Alerts - nchmf.gov.vn
Artificial Lung Market to Grow at 10.84% CAGR, Hits USD 7.05 Bn by 2034 - GlobeNewswire Inc.
Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case - Insider Monkey
United Therapeutics CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
PH-ILD hospitalization data on inhaled treprostinil — United Therapeutics at CHEST 2025 - Stock Titan
Callan Family Office LLC Increases Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (FRA:UTH) Gross-Profit-to-Asset % : 35.18% (As of Jun. 2025) - GuruFocus
UTHR (United Therapeutics) Cyclically Adjusted PB Ratio : 4.79 (As of Oct. 12, 2025) - GuruFocus
Inspire Investing LLC Trims Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
UTHR (United Therapeutics) 5-Year RORE % : 17.31% (As of Jun. 2025) - GuruFocus
UTHR (United Therapeutics) Revenue per Share : $63.53 (TTM As of Jun. 2025) - GuruFocus
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp. Hits New 52-Week High of $455.26 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $459.48 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $455.00 - Markets Mojo
United Therapeutics (NASDAQ:UTHR) Sets New 52-Week HighHere's What Happened - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
QRG Capital Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Is There Still an Opportunity in United Therapeutics After Its 25.8% Year to Date Surge? - simplywall.st
Polaris Capital Management LLC Reduces Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Hilltop National Bank Takes $341,000 Position in United Therapeutics Corporation $UTHR - MarketBeat
What Catalysts Are Reshaping the Narrative for United Therapeutics This Year? - Yahoo Finance
A Look at United Therapeutics (UTHR) Valuation as Tyvaso Shows Breakthrough Results in Late-Stage IPF Trial - simplywall.st
How Positive TETON-2 Results for Tyvaso Have Changed United Therapeutics' (UTHR) Investment Story - simplywall.st
News impact scoring models applied to United Therapeutics CorporationPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Robeco Institutional Asset Management B.V. Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock hits all-time high at 442.02 USD - Investing.com
United Therapeutics stock hits all-time high at 442.02 USD By Investing.com - Investing.com South Africa
United Therapeutics rides Tyvaso optimism as IPF trial gains momentum - S&P Global
TD Cowen maintains Buy rating on United Therapeutics stock, citing IPF opportunity - Investing.com
Jefferies reiterates Buy rating on United Therapeutics stock amid patent case - Investing.com
UBS maintains United Therapeutics stock Buy rating amid patent litigation By Investing.com - Investing.com Canada
United Therapeutics COO sells $9.49m in UTHR stock By Investing.com - Investing.com South Africa
United Therapeutics COO sells $9.49m in UTHR stock - Investing.com India
Is IPF the Next Big Market Opportunity for United Therapeutics? - Yahoo Finance
UBS maintains United Therapeutics stock Buy rating amid patent litigation - Investing.com India
United Therapeutics president Michael Benkowitz sells shares worth $3.65m - MSN
大文字化:
|
ボリューム (24 時間):